{'fraction_non_alphanumeric': 0.046296296296296294, 'fraction_numerical': 0.05555555555555555, 'mean_word_length': 5.300970873786408, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 1, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (November 2017)

The usage of biological agents is updated in Table 2. Twenty-seven percent of the treatment courses involved etanercept, which remained the commonest biological agent ever used. Etanercept was also the most frequent agent that was currently used by patients (26.9%). Figures 1—3 show the ever and current use of the biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis. https://doi.org/10.1515/hkbrd-2017-0012 Received December 11, 2017; accepted December 11, 2017